跳至主要内容
临床试验/NCT01441375
NCT01441375已完成不适用

Complications in Patients With Sickle Cell Disease and Utilization of Iron Chelation Therapy: A Retrospective Medical Records Review

Novartis Pharmaceuticals2 个研究点 分布在 1 个国家目标入组 261 人开始时间: 2011年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
261
试验地点
2
主要终点
Sickle cell complications

研究概览

简要总结

This study is a retrospective chart review of sickle cell patients and will include patients whom have received blood transfusions and those whom have not. Of the transfused patients, it will also include those whom have received chelation therapy and those whom have not.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a diagnosis of Sickle Cell Disease (SCD) and a confirmed genotype
  • Patients ≥ 16 years of age
  • Patients with ≥ 6 months of follow-up data available from first SCD treatment at the center after they reach 16 years old
  • At least one SF reading during a non-acute phase on or after the first SCD treatment at the center after they reach 16 years old

排除标准

  • Patients who participated in a clinical trial for an iron chelating medication or in a clinical trial for transfusions for SCD (1) within the six months before the index date or (2) during the patient observation period
  • Patients with sickle cell trait
  • Other protocol-defined inclusion/exclusion criteria may apply

结局指标

主要结局

Sickle cell complications

时间窗: average of 5 years

次要结局

  • Utilization of blood transfusions (patients with frequent transfusions only)(average of 5 years)
  • Burden of iron overload (patients with frequent transfusions only)(average of 5 years)
  • Overall survival(average of 5 years)
  • Utilization of health care delivery to treat sickle cell complications(average of 5 years)
  • Utilization of Iron Chelation Therapies (ICTs) (patients receiving deferoxamine or deferasirox [Exjade®] only)(average of 5 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验